Save 20% with code MAY5
0

Understanding CJC-1295:

Why DAC Forms Are Standalone and No-DAC Is Used with Ipamorelin

Growth hormone–related peptides are widely used in research to investigate endocrine regulation, GH pulsatility, and metabolic signaling pathways. Among these compounds, CJC-1295 stands out for its ability to activate the growth hormone–releasing hormone (GHRH) receptor through two distinct formulations: CJC-1295 DAC and CJC-1295 No-DAC. These two forms share an identical core peptide sequence but behave very differently in biological systems (Thorner). As a result, the DAC version is used alone, while the No-DAC version is commonly paired with Ipamorelin, a selective ghrelin receptor agonist (Ionescu & Frohman).

This blog explains the mechanistic differences between the two forms and why researchers combine No-DAC with Ipamorelin to model GH pulsatility.

What Is CJC-1295?

CJC-1295 is a synthetic peptide analog of growth hormone–releasing hormone (GHRH), engineered to activate the same receptor that endogenous GHRH uses to stimulate growth hormone (GH) secretion from the pituitary (Thorner). Unlike native GHRH, which is rapidly degraded in circulation, CJC-1295 was designed to provide greater stability, stronger receptor persistence, and more predictable activation patterns in experimental systems (Teichman et al.).

Both forms of CJC-1295, DAC and No-DAC, share an identical core sequence based on the first 29 amino acids of GHRH. This is the portion responsible for receptor binding and GH stimulation. By preserving this biologically active fragment, CJC-1295 maintains the fundamental behavior of natural GHRH while offering improved durability and experimental control (Ionescu & Frohman).

Where the two forms differ is in how long they remain active.

The No-DAC version behaves similarly to endogenous GHRH, producing short, transient bursts of receptor activity.

The DAC version includes a chemical modification that allows it to bind serum albumin, dramatically extending its half-life and supporting continuous, long-duration signaling (Thorner).

Because of this split in pharmacokinetic behavior, CJC-1295 can be used to study either pulsatile GH release or sustained GH/IGF-1 patterns, depending on which form is selected. This dual-format design is central to its use in endocrine and GH-axis research (Sackmann-Sala et al.).

What Is the DAC (Drug Affinity Complex)?

The DAC modification is a chemical group that enables CJC-1295 to bind reversibly to serum albumin. This binding dramatically increases the peptide’s resistance to enzymatic breakdown and extends its presence in circulation (Thorner; Ramírez-Andersen et al.).

As a result, CJC-1295 DAC remains active in circulation for several days, providing a long and stable half-life compared with the short duration of native GHRH. This extended presence leads to continuous GHRH receptor activation, producing a steady signaling profile rather than the brief, pulse-like activation seen with the No-DAC form (Ionescu & Frohman).

In contrast, CJC-1295 No-DAC behaves more like native GHRH, generating brief, physiologic pulses that rise and fall quickly.

Mechanistic Differences Between DAC and No-DAC

01. Pharmacokinetics and Half-Life

CJC-1295 DAC remains in circulation for days due to albumin binding, maintaining prolonged receptor exposure (Teichman et al.).

CJC-1295 No-DAC is cleared much faster, within minutes to hours, allowing researchers to study rapid, discrete GH pulses (Thorner).

02. Receptor Signaling Dynamics

DAC creates extended, continuous GHRH-R activation, useful for long-duration endocrine studies (Sackmann-Sala et al.).

No-DAC produces short, transient signals, generating a pulsatile GH pattern similar to natural physiology (Ionescu & Frohman).

03. Implications for Research Models

DAC is suited for experiments requiring sustained GH/IGF-1 exposure or long-term receptor engagement.

No-DAC is preferred when researchers need controlled timing, GH peaks, or pulse-based endocrine dynamics.

What Is Ipamorelin?

Ipamorelin is a selective agonist of the ghrelin receptor (GHS-R1a). It stimulates GH release through the ghrelin pathway with high specificity and minimal influence on other hormones such as cortisol or prolactin (Benso et al.).

Ipamorelin is widely used to model:

GH pulsatility

pituitary responsiveness to GHS-R1a activation

metabolic and nutrient-signaling pathways related to GH release (Ueberberg et al.).

Because Ipamorelin is short-acting, it aligns naturally with GHRH-based peptides that also produce rapid signals.

Why Is CJC-1295 No-DAC Combined with Ipamorelin

Dual-Pathway Synergy (GHRH + GHS)

No-DAC activates the GHRH pathway. Ipamorelin activates the GHS-R1a pathway.
Together, they produce a dual-pathway GH pulse that is stronger than either pathway alone (Veldhuis & Bowers). This makes the combination useful for models examining cooperative pituitary signaling.

Timing Compatibility

Both peptides are short-acting, allowing researchers to coordinate the timing of GHS and GHRH signals precisely. This enables controlled pulsatile GH release, which closely mirrors natural physiology (Thorner).

Avoiding Kinetic Mismatch With DAC

CJC-1295 DAC signals continuously for days. Ipamorelin signals for minutes.
Pairing them results in poor synchronization, with the short GHS signal unable to meaningfully interact with prolonged GHRH receptor activation (Ishida et al.).

This kinetic mismatch is the main reason DAC is not combined with Ipamorelin.

To learn more about the combination of CJC-1295 and Ipamorelin, see:

Why Is CJC-1295 DAC Used Alone

  1. Extended Signaling Window – DAC’s purpose is to provide long-duration GHRH receptor stimulation. Adding a short-acting GHS would not meaningfully influence the already-extended signaling pattern (Teichman et al.; Ionescu & Frohman).
  2. Unsuitable for Pulsatile Combination – Ipamorelin produces fast GH spikes. The DAC form does not spike, it remains elevated. Because the physiological timing of GH release is central in many experimental designs, DAC is used independently rather than combined (Ionescu & Frohman).
  3. Research Application Focus – CJC-1295 DAC is especially relevant for studies examining:

This makes it a standalone tool for steady-state GH axis research.

Research Applications and Experimental Contexts

CJC-1295—both the DAC and No-DAC forms—appears across several areas of GH-axis and endocrine research, with each version selected according to the type of signaling model required. Because their pharmacokinetic profiles differ significantly, researchers choose between continuous GH exposure or precisely timed GH pulses depending on experimental goals (Teichman et al.; Ionescu & Frohman).

CJC-1295 is widely used in research exploring growth hormone secretion, pituitary responsiveness, and downstream IGF-1 regulation. Studies suggest that the DAC form is useful for examining long-duration GH and IGF-1 patterns, sustained receptor activation, and extended endocrine feedback loops (Sackmann-Sala et al.). By contrast, CJC-1295 No-DAC is frequently used in models requiring short, physiologic GHRH-like pulses (Thorner).

Because GH and IGF-1 influence nutrient handling and metabolic balance, CJC-1295 has been applied in models investigating lipid turnover, substrate utilization, and metabolic adaptation (Veldhuis et al.). Research suggests that the DAC form helps explore long-term metabolic responses, while the No-DAC form is useful for studying transient GH-linked changes in energy regulation.

CJC-1295 No-DAC appears in studies designed to examine receptor activation timing and pituitary signaling kinetics (Ionescu & Frohman). These models help researchers investigate how quickly the pituitary responds to GHRH input, how receptor exposure affects GH release patterns, and how short-interval pulses influence overall GH output.

Research combining CJC-1295 No-DAC with Ipamorelin uses both peptides to study dual-pathway GH signaling, where the GHRH and GHS-R1a pathways are activated simultaneously (Ishida et al.). These models allow researchers to evaluate coordinated GH pulses, timing-dependent signaling interactions, and pathway cooperation. Because CJC-1295 DAC produces prolonged receptor activation, it is not used in studies requiring synchronized, short-acting signals.

Comparative Overview

Feature CJC-1296 DAC CJC-1295 No-DAC Ipamorelin
Half‑Life Days – prolonged by albumin binding (Teichman et al.) Minutes–hours – rapidly cleared like native GHRH (Sackmann-Sala et al.) Minutes – short-acting with rapid peak (Gobburu et al.)
Primary Pathway GHRH‑R (continuous stimulation) (Teichman et al.) GHRH‑R (pulsatile) (Thorner) GHS‑R1a (selective ghrelin receptor agonist) (Raun et al.)
Signaling Pattern Steady signaling over days (Teichman et al.) Pulsed – mimics physiological GHRH (Sackmann-Sala et al.) Pulsed – sharp and brief GH spikes (Gobburu et al.)
Research Use Long-term GH/IGF-1 studies (Teichman et al.) GH pulse models and pituitary response timing (Ionescu & Frohman) GH spike and GHS-R1a specificity studies (Raun et al.)
Combination Compatibility Used alone – long-acting, unsuitable for pulse pairing (Ionescu & Frohman) Paired with Ipamorelin – matched timing for synergy (Veldhuis & Bowers) Paired with No-DAC – dual-pathway pulsed GH release (Ishida et al.)

Where to Get CJC-1295 and Ipamorelin for Research

Tydes provides research-grade CJC-1295 and Ipamorelin, manufactured under GMP-certified conditions and verified through independent third-party testing. Each peptide is accompanied by a Certificate of Analysis (COA) confirming purity and identity, with temperature-controlled storage and shipping to maintain stability.

CJC-1295 exists in two mechanistically distinct formats, and their differences explain why one is paired with Ipamorelin while the other is used alone. CJC-1295 DAC is engineered for long-duration GHRH receptor activation and therefore functions as a standalone tool for sustained endocrine studies (Teichman et al.). CJC-1295 No-DAC, with its short-acting and pulse-compatible profile, aligns well with Ipamorelin, allowing researchers to explore synchronized GH pulses through dual-pathway activation (Ionescu & Frohman; Veldhuis & Bowers).

Together, these peptides provide flexible, well-characterized systems for studying GH signaling, endocrine modulation, metabolic pathways, and pituitary responsiveness in controlled research settings.
0
0
Your Cart
Your cart is emptyReturn to Shop
Continue Shopping